Page 52 - Biomarkers for risk stratification and guidance in heart failure
P. 52

                                Table 1. Baseline characteristics.
Characteristics
Baseline
Age, yrs
Female
Hypertension
Diabetes mellitus Transient ischemic attack Stroke
COPD
Atrial fibrillation -Chronic
-Paroxysmal
Coronary artery disease Myocardial infarction PCI
CABG
Valve replacement Pacemaker
ICD
History of HF
-Ischemic -Non-ischemic
cause unknown Discharge
NYHA functional class
I II III
LVEF, %
Mitral regurgitation grade ≥II Systolic BP, mmHg
Diastolic BP, mmHg
HR, beats/min
Sodium, mmol/l
Potassium, mmol/l
Urea, U/l
Creatinine, U/l
Hemoglobin, mmol/l NT-proBNP, pg/ml
Admission Discharge Target
NT-proBNP Guided (n=174)
71.6 ±2.0 79 (45.4) 83 (47.7) 44 (25.3) 8 (4.6) 17 (9.8) 29 (16.7)
29 (16.7) 28 (16.1) 97 (55.7) 65 (37.4) 20 (11.5) 32 (18.4) 11 (6.3) 11 (6.3) 13 (7.5)
40 (23.0) 26 (14.9) 1 (0.6)
20 (11.5)
113 (64.9)
41 (23.6)
34.9 ±13.7
84 ±48.3
116.8 ±18.5
68.7 ±11.3
72.1 ±11.4
139.5 ±3.2
4.27 ±0.46
11.5 (8.2–16.2) 121 (97.8–157.3) 8.5 ±1.2
8,034 (4,210–13,831) 2,961 (1,383–5,144) 2,491 (1,109–4,435)
Clinically P-value Guided (n=171)
72.8 ±11.7 NS
69 (40.3) NS
84 (49.1) NS
47 (27.5) NS
25 (14.6) 0.002
18 (10.5) NS
30 (17.5) NS 3
NS
29 (17.0)
26 (15.2)
109 (63.7) NS 74 (43.3) NS 24 (14.0) NS 29 (17.0) NS 9 (5.3) NS 21 (12.3) NS 10 (5.8) NS
Management of chronic heart failure guided by individual NT-proBNP targets.
  33 (19.3) 26 (15.2)
NS
0 NS
17 (9.9) NS
121 (70.8)
33 (19.3)
36.7 ±14.8 NS 63 ±36.8 NS 119.4 ±22.4 NS 69.2 ±11.6 NS 74.5 ±16.1 NS 139.1 ±3.8 NS 4.27 ±0.46 NS 11.9 (9.0–16.0) NS 126 (104.0–166.3) NS 8.4 ±1.3 NS
NS 2,936 (1,291–5,525) NS
8,168 (4,288–14,051)
 Data is presented as mean±standard deviation, median(interquartile range) or frequency(%). COPD=chronic obstructive pulmonary disease; PCI=percutaneous coronary intervention; CABG=coronary artery bypass grafting; ICD=internal cardioverter defibrillator; HF=heart failure; LVEF= left ventricular ejection fraction; BP=blood pressure; HR=heart rate; NT-proBNP=N-terminal pro-B-type natriuretic peptide.
51
 





























   50   51   52   53   54